Cormorant Capital

Cormorant Capital

Cormorant Capital

Suggest edits
Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 3

Portfolio

Portfolio Tracker

Add info
Xconomy

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia

MyoKardia
MyoKardia
BridgeBio
BridgeBio
Perceptive Advisors
Perceptive Advisors
Xconomy

BridgeBio's Pipeline Expansion Continues as Portfolio's Milestones Approach

BridgeBio
BridgeBio
Technical.ly Philly

University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO

Cabaletta Bio
Cabaletta Bio
PE HUB

VC-backed Cabaletta Bio begins trading on NASDAQ

Cabaletta Bio
Cabaletta Bio
Xconomy

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

BridgeBio
BridgeBio
PE HUB

Satsuma Pharmaceuticals goes public

Satsuma Pharmaceuticals
Satsuma Pharmaceuticals
Xconomy

BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut

BridgeBio
BridgeBio
MedCity News

BridgeBio files for $225M initial public offering

BridgeBio
BridgeBio
$299,200,000 Venture capital
PE HUB

BridgeBio Pharma racks up $299.2 mln

BridgeBio
BridgeBio
$50,000,000 Venture capital (Series B)
MedCity News , FinSMEs

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

Cabaletta Bio
Cabaletta Bio
Xconomy

BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup

Health Science
Novartis
Novartis
BridgeBio
BridgeBio
Xconomy

BridgeBio Bags $135M For “Hub and Spoke” Rare Disease Drug R&D

Health Funding
BridgeBio
BridgeBio
$12,000,000 Venture capital (Series A)
PE Hub

Satsuma Pharmaceuticals takes in $12 mln Series A